콜레스테롤 시장 - 성장, 향후 전망, 경쟁 분석(2023-2031년)

The cholesterol market is expected to experience a CAGR of 7.7% during the forecast period of 2023 to 2031, driven by several key drivers that have played a pivotal role in shaping the industry landscape. The cholesterol market's growth is fueled by drivers such as the increasing prevalence of cardiovascular diseases, the growing focus on preventive healthcare, and advancements in drug development. Yet, safety concerns and potential side effects have introduced a complex restraint that necessitates careful consideration. Geographically, regions present varying trends, while competitive dynamics underscore key players' strategies to navigate evolving industry demands. As the market progresses from 2023 to 2031, the cholesterol market is positioned for continued growth, driven by technological advancements, shifting healthcare paradigms, and the imperative to improve cardiovascular health.

Increasing Prevalence of Cardiovascular Diseases

The escalating prevalence of cardiovascular diseases has been a major driver propelling the cholesterol market. Elevated cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol, have been identified as a major risk factor for heart diseases. This recognition has led to heightened awareness among healthcare professionals and patients alike, driving the demand for cholesterol-lowering interventions. Companies like Company A have developed innovative therapies targeting LDL cholesterol reduction, which have garnered significant attention due to their potential to mitigate cardiovascular risks. The substantial burden of cardiovascular diseases has underscored the critical need for effective cholesterol management, thereby fueling market growth.

Growing Focus on Preventive Healthcare

The shift towards preventive healthcare practices has bolstered the demand for cholesterol management solutions. Individuals are becoming increasingly proactive in managing their health to prevent the onset of chronic conditions. This proactive approach has driven the adoption of cholesterol screening and management as part of routine healthcare check-ups. Moreover, healthcare providers are emphasizing lifestyle modifications and dietary interventions to control cholesterol levels. Company B's comprehensive approach, encompassing dietary counseling, exercise recommendations, and cholesterol-lowering medications, exemplifies the industry's response to the growing emphasis on preventive healthcare strategies.

Advancements in Drug Development

Remarkable advancements in drug development have significantly contributed to the cholesterol market's expansion. Pharmaceutical companies have introduced novel therapies that target cholesterol biosynthesis, absorption, and metabolism. These therapies offer patients diverse options to effectively manage cholesterol levels. Notably, Company C has unveiled groundbreaking treatments that harness the power of genetic insights to tailor cholesterol management strategies. Such innovations in drug development have transformed the treatment landscape, offering promising avenues for patients seeking personalized and effective cholesterol management solutions.

Safety Concerns and Side Effects

Despite the market's growth, safety concerns and potential side effects associated with cholesterol-lowering medications have emerged as significant restraints. Certain cholesterol-lowering drugs, such as statins, have been associated with adverse effects like muscle pain, liver dysfunction, and diabetes. These concerns have led to hesitancy among some patients and healthcare providers to initiate cholesterol-lowering therapies, particularly in cases where the potential benefits are weighed against potential risks. Striking a balance between the benefits and risks of cholesterol management interventions remains a complex challenge for both patients and healthcare professionals.

Market Segmentation by Type: LDL Cholesterol-Related Products Dominate the Market

The cholesterol market can be segmented by type, encompassing low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and very-low-density lipoprotein (VLDL) cholesterol. In terms of revenue in 2022, LDL cholesterol-related products dominated the market, given their pivotal role in cardiovascular risk assessment and management. However, during the forecast period from 2023 to 2031, HDL cholesterol-related products are expected to exhibit the highest Compound Annual Growth Rate (CAGR). The recognition of HDL cholesterol's protective effects on cardiovascular health and the development of innovative therapies targeting HDL functionality underpin this projected growth.

Market Segmentation by Source: Animal-Derived Products Dominate the Market

Market segmentation by source includes plant-derived, animal-derived, and synthetic cholesterol-related products. In 2022, animal-derived products represented the highest revenue percentage, driven by the prevalence of cholesterol-rich animal-based food sources and the established use of animal-derived cholesterol in research and diagnostic applications. Meanwhile, during the forecast period of 2023 to 2031, plant-derived products are expected to achieve the highest CAGR. The increasing adoption of plant-based diets, driven by health and sustainability considerations, contributes to the anticipated growth of plant-derived cholesterol products.

North America Remains as the Global Leader

Geographically, the cholesterol market showcases diverse trends, with varying revenue contributions and growth rates across regions. The Asia-Pacific region is poised to register the highest CAGR during the forecast period of 2023 to 2031. Rapid urbanization, changing dietary patterns, and increasing healthcare awareness in countries like China and India drive the region's robust growth prospects. However, North America maintained the highest revenue percentage in 2022, attributed to the high prevalence of cardiovascular diseases, sophisticated healthcare infrastructure, and a strong focus on preventive healthcare practices.

Market Competition to Intensify during the Forecast Period

Within the cholesterol market, several key players have emerged as industry leaders, each employing distinct strategies to secure their competitive foothold and expand market share. These strategies encompass research and development investments, strategic partnerships, market expansion, and patient-centric approaches. Leading companies such as Chongqing Jingkang Biotechnology Co., Ltd. CARBOGEN AMCIS, Zhejiang Garden Biochemical High-Tech Stock Co., Ltd, Avanti Polar Lipids, Inc., Anhui Chem-Bright Bioengineering Co., Ltd., Rocky Mountain Biologicals, Lee BioSolutions, Inc., Cone Bioproducts, Beckman Coulter, Alfa Wassermann Diagnostic Technologies, LLC, have exhibited robust financial performance in 2022, driven by their ability to offer innovative cholesterol management solutions. These players are expected to leverage their scientific expertise, enhance therapeutic offerings, and capitalize on emerging opportunities to maintain growth from 2023 to 2031. The forecast period is anticipated to witness increased collaborations between pharmaceutical companies, research institutions, and healthcare providers to develop comprehensive cholesterol management strategies that cater to diverse patient needs.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofCholesterol market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Cholesterol market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

Low-density Lipoprotein (LDL)

High-density Lipoprotein (HDL)

Very-low-density Lipoprotein (VLDL)

Source

Plant-derived

Animal-derived

Synthetic

End-use

Pharmaceutical

Cosmetics

Food & Beverage

Animal Feed

Industrial Products

Others

Region Segment (2021-2031; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Cholesterol market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2031.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Cholesterol market?

Which is the largest regional market for Cholesterol market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Cholesterol market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Cholesterol market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Cholesterol Market
• 2.2. Global Cholesterol Market, By Type, 2022 (US$ Million)
• 2.3. Global Cholesterol Market, By Source, 2022 (US$ Million)
• 2.4. Global Cholesterol Market, By End-use, 2022 (US$ Million)
• 2.5. Global Cholesterol Market, By Geography, 2022 (US$ Million)
• 2.6. Attractive Investment Proposition by Geography, 2022

3. Cholesterol Market: Competitive Analysis

• 3.1. Market Positioning of Key Cholesterol Market Vendors
• 3.2. Strategies Adopted by Cholesterol Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2022 Versus 2031

4. Cholesterol Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Cholesterol Market Value, 2021 - 2031, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis

5. Cholesterol Market: By Type, 2021-2031, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2022 Versus 2031
• 5.3. Market Segmentation
  • 5.3.1. Low-density Lipoprotein (LDL)
  • 5.3.2. High-density Lipoprotein (HDL)
  • 5.3.3. Very-low-density Lipoprotein (VLDL)

6. Cholesterol Market: By Source, 2021-2031, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2022 Versus 2031
• 6.3. Market Segmentation
  • 6.3.1. Plant-derived
  • 6.3.2. Animal-derived
  • 6.3.3. Synthetic

7. Cholesterol Market: By End-use, 2021-2031, USD (Million)

• 7.1. Market Overview
• 7.2. Growth & Revenue Analysis: 2022 Versus 2031
• 7.3. Market Segmentation
  • 7.3.1. Pharmaceutical
  • 7.3.2. Cosmetics
  • 7.3.3. Food & Beverage
  • 7.3.4. Animal Feed
  • 7.3.5. Industrial Products
  • 7.3.6. Others

8. North America Cholesterol Market, 2021-2031, USD (Million)

• 8.1. Market Overview
• 8.2. Cholesterol Market: By Type, 2021-2031, USD (Million)
• 8.3. Cholesterol Market: By Source, 2021-2031, USD (Million)
• 8.4. Cholesterol Market: By End-use, 2021-2031, USD (Million)
• 8.5.Cholesterol Market: By Region, 2021-2031, USD (Million)
  • 8.5.1.North America
    • 8.5.1.1. U.S.
      • 8.5.1.1.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 8.5.1.1.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 8.5.1.1.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 8.5.1.2. Canada
      • 8.5.1.2.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 8.5.1.2.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 8.5.1.2.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 8.5.1.3. Rest of North America
      • 8.5.1.3.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 8.5.1.3.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 8.5.1.3.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)

9. UK and European Union Cholesterol Market, 2021-2031, USD (Million)

• 9.1. Market Overview
• 9.2. Cholesterol Market: By Type, 2021-2031, USD (Million)
• 9.3. Cholesterol Market: By Source, 2021-2031, USD (Million)
• 9.4. Cholesterol Market: By End-use, 2021-2031, USD (Million)
• 9.5.Cholesterol Market: By Region, 2021-2031, USD (Million)
  • 9.5.1.UK and European Union
    • 9.5.1.1. UK
      • 9.5.1.1.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 9.5.1.1.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 9.5.1.1.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 9.5.1.2. Germany
      • 9.5.1.2.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 9.5.1.2.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 9.5.1.2.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 9.5.1.3. Spain
      • 9.5.1.3.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 9.5.1.3.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 9.5.1.3.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 9.5.1.4. Italy
      • 9.5.1.4.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 9.5.1.4.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 9.5.1.4.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 9.5.1.5. France
      • 9.5.1.5.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 9.5.1.5.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 9.5.1.5.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 9.5.1.6. Rest of Europe
      • 9.5.1.6.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 9.5.1.6.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 9.5.1.6.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)

10. Asia Pacific Cholesterol Market, 2021-2031, USD (Million)

• 10.1. Market Overview
• 10.2. Cholesterol Market: By Type, 2021-2031, USD (Million)
• 10.3. Cholesterol Market: By Source, 2021-2031, USD (Million)
• 10.4. Cholesterol Market: By End-use, 2021-2031, USD (Million)
• 10.5.Cholesterol Market: By Region, 2021-2031, USD (Million)
  • 10.5.1.Asia Pacific
    • 10.5.1.1. China
      • 10.5.1.1.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 10.5.1.1.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 10.5.1.1.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 10.5.1.2. Japan
      • 10.5.1.2.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 10.5.1.2.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 10.5.1.2.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 10.5.1.3. India
      • 10.5.1.3.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 10.5.1.3.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 10.5.1.3.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 10.5.1.4. Australia
      • 10.5.1.4.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 10.5.1.4.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 10.5.1.4.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 10.5.1.5. South Korea
      • 10.5.1.5.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 10.5.1.5.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 10.5.1.5.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 10.5.1.6. Rest of Asia Pacific
      • 10.5.1.6.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 10.5.1.6.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 10.5.1.6.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)

11. Latin America Cholesterol Market, 2021-2031, USD (Million)

• 11.1. Market Overview
• 11.2. Cholesterol Market: By Type, 2021-2031, USD (Million)
• 11.3. Cholesterol Market: By Source, 2021-2031, USD (Million)
• 11.4. Cholesterol Market: By End-use, 2021-2031, USD (Million)
• 11.5.Cholesterol Market: By Region, 2021-2031, USD (Million)
  • 11.5.1.Latin America
    • 11.5.1.1. Brazil
      • 11.5.1.1.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 11.5.1.1.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 11.5.1.1.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 11.5.1.2. Mexico
      • 11.5.1.2.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 11.5.1.2.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 11.5.1.2.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 11.5.1.3. Rest of Latin America
      • 11.5.1.3.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 11.5.1.3.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 11.5.1.3.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)

12. Middle East and Africa Cholesterol Market, 2021-2031, USD (Million)

• 12.1. Market Overview
• 12.2. Cholesterol Market: By Type, 2021-2031, USD (Million)
• 12.3. Cholesterol Market: By Source, 2021-2031, USD (Million)
• 12.4. Cholesterol Market: By End-use, 2021-2031, USD (Million)
• 12.5.Cholesterol Market: By Region, 2021-2031, USD (Million)
  • 12.5.1.Middle East and Africa
    • 12.5.1.1. GCC
      • 12.5.1.1.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 12.5.1.1.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 12.5.1.1.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 12.5.1.2. Africa
      • 12.5.1.2.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 12.5.1.2.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 12.5.1.2.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 12.5.1.3. Rest of Middle East and Africa
      • 12.5.1.3.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 12.5.1.3.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 12.5.1.3.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)

13. Company Profile

• 13.1. Chongqing Jingkang Biotechnology Co., Ltd.
  • 13.1.1. Company Overview
  • 13.1.2. Financial Performance
  • 13.1.3. Product Portfolio
  • 13.1.4. Strategic Initiatives
• 13.2. CARBOGEN AMCIS
  • 13.2.1. Company Overview
  • 13.2.2. Financial Performance
  • 13.2.3. Product Portfolio
  • 13.2.4. Strategic Initiatives
• 13.3. Zhejiang Garden Biochemical High-Tech Stock Co., Ltd
  • 13.3.1. Company Overview
  • 13.3.2. Financial Performance
  • 13.3.3. Product Portfolio
  • 13.3.4. Strategic Initiatives
• 13.4. Avanti Polar Lipids, Inc.
  • 13.4.1. Company Overview
  • 13.4.2. Financial Performance
  • 13.4.3. Product Portfolio
  • 13.4.4. Strategic Initiatives
• 13.5. Anhui Chem-Bright Bioengineering Co., Ltd.
  • 13.5.1. Company Overview
  • 13.5.2. Financial Performance
  • 13.5.3. Product Portfolio
  • 13.5.4. Strategic Initiatives
• 13.6. Rocky Mountain Biologicals
  • 13.6.1. Company Overview
  • 13.6.2. Financial Performance
  • 13.6.3. Product Portfolio
  • 13.6.4. Strategic Initiatives
• 13.7. Lee BioSolutions, Inc.
  • 13.7.1. Company Overview
  • 13.7.2. Financial Performance
  • 13.7.3. Product Portfolio
  • 13.7.4. Strategic Initiatives
• 13.8. Cone Bioproducts
  • 13.8.1. Company Overview
  • 13.8.2. Financial Performance
  • 13.8.3. Product Portfolio
  • 13.8.4. Strategic Initiatives
• 13.9. Beckman Coulter
  • 13.9.1. Company Overview
  • 13.9.2. Financial Performance
  • 13.9.3. Product Portfolio
  • 13.9.4. Strategic Initiatives
• 13.10. Alfa Wassermann Diagnostic Technologies, LLC
  • 13.10.1. Company Overview
  • 13.10.2. Financial Performance
  • 13.10.3. Product Portfolio
  • 13.10.4. Strategic Initiatives
• 13.11. Other Notable Players
  • 13.11.1. Company Overview
  • 13.11.2. Financial Performance
  • 13.11.3. Product Portfolio
  • 13.11.4. Strategic Initiatives